Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Sells $110,840.00 in Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction on Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the transaction, the chief executive officer now directly owns 428,976 shares in the company, valued at approximately $47,547,699.84. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ opened at $119.08 on Friday. The company has a market capitalization of $7.35 billion, a PE ratio of 20.46, a P/E/G ratio of 1.37 and a beta of 0.57. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.26. The firm has a fifty day simple moving average of $110.49 and a 200 day simple moving average of $109.68.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Wednesday, November 6th. The specialty pharmaceutical company reported $5.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.54 by $1.32. The firm had revenue of $1.05 billion for the quarter, compared to analysts’ expectations of $1.04 billion. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. On average, sell-side analysts forecast that Jazz Pharmaceuticals plc will post 16.02 EPS for the current year.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of large investors have recently bought and sold shares of JAZZ. Swiss National Bank raised its holdings in shares of Jazz Pharmaceuticals by 0.3% during the third quarter. Swiss National Bank now owns 117,000 shares of the specialty pharmaceutical company’s stock valued at $13,035,000 after purchasing an additional 400 shares during the period. Natixis Advisors LLC increased its position in Jazz Pharmaceuticals by 7.6% in the 3rd quarter. Natixis Advisors LLC now owns 22,834 shares of the specialty pharmaceutical company’s stock valued at $2,544,000 after buying an additional 1,603 shares in the last quarter. CIBC Asset Management Inc acquired a new position in Jazz Pharmaceuticals during the 3rd quarter worth approximately $209,000. Kovack Advisors Inc. raised its stake in Jazz Pharmaceuticals by 20.4% during the 3rd quarter. Kovack Advisors Inc. now owns 57,672 shares of the specialty pharmaceutical company’s stock worth $6,425,000 after buying an additional 9,783 shares during the period. Finally, MQS Management LLC bought a new position in Jazz Pharmaceuticals in the third quarter worth approximately $253,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on JAZZ shares. Needham & Company LLC reiterated a “buy” rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday. StockNews.com raised Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Royal Bank of Canada lifted their price objective on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 23rd. Morgan Stanley lowered their target price on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a research note on Friday, July 12th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $140.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Three equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $175.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.